Drug Safety

, Volume 19, Issue 1, pp 1–10 | Cite as

The Role of the WHO Programme on International Drug Monitoring in Coordinating Worldwide Drug Safety Efforts

Leading Article


The rationale for setting up the WHO International Programme for Adverse Reaction Monitoring, 30 years ago was to make it possible to identify rare adverse drug reactions (ADRs) that could not be found through clinical trial programmes. It became evident that maintaining an international database of ADR case reports and a network of institutions and scientists concerned with drug safety issues provides great additional gains when compared with operating in isolation. Thus, the scope of the WHO programme has expanded over time to accommodate the expansion of the field of drug safety monitoring, now often named pharmacovigilance. The international centre, the WHO Collaborating Centre for International Drug Monitoring in Uppsala [now known as the Uppsala Monitoring Centre (UMC)], maintains the international database and serves the national centres associated with the WHO programme; however, the role of the centre is expanding allowing it to play a leading role in global drug safety monitoring.

The national centres are appointed by the governments of each of the countries participating in the WHO programme. These centres are responsible for collecting spontaneous ADR reports originating from health professionals. 49 countries are currently contributing case information and are full members of the programme; an additional 11 countries have applied for membership but have still not submitted any reports. The annual influx of reports is currently fluctuating at around 150 000 reports.

In its development, the data collected by the WHO programme was guarded by strong rules of confidentiality. In some member countries, however, case data, with the important exception of reporter and patient identities, has always been public information. The UMC has made it a priority to try to create an atmosphere of openness and trust between all parties involved in drug safety assessment, which will eventually enable general sharing of available data and an extended analysis and use of the data collected. The WHO network represents the wealth of competence and experience that is at the disposal of countries wishing to join the international pharmacovigilance community.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Edwards IR, Fucik H. Impact and credibility of the WHO adverse reaction signals. Drug Inf J 1996; 30: 461–4CrossRefGoogle Scholar
  2. 2.
    Olsson S, Biriell C, Boman G. Photosensitivity during treatment with azapropazone. BMJ 1985; 291: 939PubMedCrossRefGoogle Scholar
  3. 3.
    Stricker BHCh, Meyboom RHB, Lindquist M. Acute hypersensitivity reactions to paracetamol. BMJ 1985; 291: 938–9PubMedCrossRefGoogle Scholar
  4. 4.
    Stricker BHCh, van Dijke CPH, Isaacs AJ, et al. Skin reactions to terfenadine. BMJ 1986; 293: 536PubMedCrossRefGoogle Scholar
  5. 5.
    Strieker BHCh, Biriell C. Skin reactions and fever with indapamide. BMJ 1987; 295: 1313–4CrossRefGoogle Scholar
  6. 6.
    Strieker BHCh, Slagboom G, Demeaseneer R, et al. Anaphylactic reactions to Cinoxacin. BMJ 1988; 297: 1434–5CrossRefGoogle Scholar
  7. 7.
    Biriell C, McEwen J, Sanz E. Depression associated with diltiazem [letter]. BMJ 1989; 299: 796PubMedCrossRefGoogle Scholar
  8. 8.
    Li D, Lindquist M, Edwards IR. Evaluation of early signals of drug-induced Stevens-Johnson Syndrome in the WHO ADR data base. Pharmacoepidemiol Drug Saf 1992; 1: 11–8CrossRefGoogle Scholar
  9. 9.
    Lindquist M, Edwards IR. Endocrine adverse effects of omeprazole. BMJ 1992; 305: 451–2PubMedCrossRefGoogle Scholar
  10. 10.
    Olsson S, Edwards IR. Tachycardia during cisapride treatment. BMJ 1992; 305: 748–9PubMedCrossRefGoogle Scholar
  11. 11.
    Meyboom RHB, Olsson S, Knol A, et al. Achilles tendinitis induced by Pefloxacin and other fluoroquinolone derivatives. Pharmacoepidemiol Drug Saf 1994; 3: 185–9CrossRefGoogle Scholar
  12. 12.
    Fraunfelder FT, Edwards IR. Possible ocular adverse effects associated with leuprolide injections. JAMA 1995; 273(10): 773–4PubMedCrossRefGoogle Scholar
  13. 13.
    Meyboom RHB, Fucik H, Edwards IR. Thrombocytopenia reported in association with hepatitis B and A vaccines [letter]. Lancet 1995; 345: 1638PubMedCrossRefGoogle Scholar
  14. 14.
    Alder J, Fraunfelder FT, Edwards IR. Levonorgestrel implants and intracranial hypertension. N Engl J Med 1995; 332(25): 1720–1PubMedCrossRefGoogle Scholar
  15. 15.
    Lindquist M, Edwards IR. Risks of non-sedating antihistamines [letter]. Lancet 1997; 349: 1322PubMedCrossRefGoogle Scholar
  16. 16.
    US Department of Health and Human Services. Health Advisory on Fenfluramine/Phentermine for Obesity. HHS News 1997 Jul 8Google Scholar
  17. 17.
    Edwards IR. Adverse Drug Reactions: Finding the needle in the haystack [editorial]. BMJ 1997; 315: 500PubMedCrossRefGoogle Scholar
  18. 18.
    Finney DJ. Systematic signalling of adverse reactions to drugs. Meth Inform Med 1974; 13: 1–10PubMedGoogle Scholar
  19. 19.
    Lindquist M, Sanderson J, Claesson C, et al. New pharmacovigilance information on an old drug — an international study of spontaneous reports on digoxin. Drug Invest 1994; 8(2): 73–80CrossRefGoogle Scholar
  20. 20.
    Lindquist M, Pettersson M, Edwards IR, et al. Omeprazole and visual disorders: seeing alternatives. Pharmacoepidemiol Drug Saf 1996; 5: 27–32PubMedCrossRefGoogle Scholar
  21. 21.
    Lindquist M, Pettersson M, Edwards IR, et al. How does cystitis affect a comparative risk profile of tiaprofenic acid with other non-steroidal antiinflammatory drugs? An international study based on spontaneous reports and drug usage data. Pharmacol Toxicol 1997; 80: 211–7PubMedCrossRefGoogle Scholar
  22. 22.
    Lindquist M, Pettersson M, Edwards IR, et al. Withdrawal reactions with selective serotonin reuptake inhibitors (SSRIs) as reported to the WHO system. Eur J Clin Pharmacol 1997; 53: 163–9PubMedCrossRefGoogle Scholar
  23. 23.
    McNamee D. Speaking about pharmacovigilance [editorial]. Lancet 1996; 348: 908PubMedCrossRefGoogle Scholar
  24. 24.
    Edwards IR, Hugman B. The challenge of effectively communicating risk-benefit information. Drug Saf 1997; 17(4): 216–27PubMedCrossRefGoogle Scholar
  25. 25.
    Olsson S, editor. National pharmacovigilance systems-country profiles and overview. Uppsala: The Uppsala Monitoring Centre, 1997Google Scholar
  26. 26.
    Nainggolan L. Heart valve problems first seen with obesity drugs in 1994/5. Scrip 1997; No 2294: 20Google Scholar
  27. 27.
    Bate A, Lindquist M, Edwards IR, et.al. ABayesian neural network method for adverse drug reaction signal detection. Eur J Clin Pharmacol. In pressGoogle Scholar
  28. 28.
    McNamee D. Communicating drug safety information. Lancet 1997; 350: 1646PubMedCrossRefGoogle Scholar
  29. 29.
    The Erice Declaration on Communicating Drug Safety Information, HAInews 1997; No 98: 9Google Scholar
  30. 30.
    Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf 1994; 10: 93–102PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  1. 1.External AffairsThe Uppsala Monitoring CentreUppsalaSweden

Personalised recommendations